Although experiments in vitro and in mouse models of diabetes suggest a potential role of GM3 in competing with the insulin–insulin receptor interaction and to contribute to T2D, robust evidence using GM3 synthase specific inhibitors is needed. The gene discussed is INS; the disease is type 2 diabetes mellitus.